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Abstract
Background: Intermittent preventive treatment with sulphadoxine-pyrimethamine for pregnant
women (IPTp-SP) is currently being scaled up in many countries in sub-Saharan Africa. Despite high
antenatal clinic (ANC) attendance, coverage with the required two doses of SP remains low. The
study investigated whether a targeted community-based promotion campaign to increase ANC
attendance and SP uptake could effectively improve pregnancy outcomes in the community.
Methods: Between 2004 and 2006 twelve health centres in Boromo Health District, Burkina Faso
were involved in this study. Four were strategically assigned to community promotion in addition
to IPTp-SP (Intervention A) and eight were randomly allocated to either IPTp-SP (Intervention B)
or weekly chloroquine (Control). Primi- and secundigravidae were enrolled at village level and thick
films and packed cell volume (PCV) taken at 32 weeks gestation and at delivery. Placental smears
were prepared and newborns weighed. Primary outcomes were peripheral parasitaemia during
pregnancy and at delivery, placental malaria, maternal anaemia, mean and low birth weight.
Secondary outcomes were the proportion of women with ≥ 3 ANC visits and ≥ 2 doses of SP.
Intervention groups were compared using logistic and linear regression with linearized variance
estimations to correct for the cluster-randomized design.
Results: SP uptake (≥ 2 doses) was higher with (Intervention A: 70%) than without promotion
(Intervention B: 49%) (OR 2.45 95%CI 1.25–4.82 p = 0.014). Peripheral (33.3%) and placental
(30.3%) parasite rates were significantly higher in the control arm compared to Intervention B
(peripheral: 20.1% OR 0.50 95%CI 0.37–0.69 p = 0.001; placental: 20.5% OR 0.59 95%CI 0.44–0.78
p = 0.002) but did not differ between Intervention A (17.4%; 18.1%) and Intervention B (20.1;
20.5%) (peripheral: OR 0.84 95%CI 0.60–1.18 p = 0.280; placental: OR 0.86 95%CI 0.58–1.29 p =
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0.430). Mean PCV and birth weight and prevalence of anaemia and low birth weight did not differ
between study arms.
Conclusion: The promotional campaign resulted in a major increase in IPTp-coverage, with two
thirds of women at delivery having received ≥ 2 SP. Despite lower prevalence of malaria infection
this did not translate into a significant difference in maternal anaemia or birth weight. This data
provides evidence that, as with immunization programmes, extremely high coverage is essential for
effectiveness. This critical threshold of coverage needs to be defined, possibly on a regional basis.
Background
Each year, about 50 million women living in malaria
endemic regions become pregnant, more than half in sub-
Saharan Africa [1]. In areas of relatively stable transmis-
sion, where acquired immunity to Plasmodium falciparum
limits infection and prevents severe disease in adults,
women in their first and second pregnancy are the most
vulnerable [2], due to a higher risk of severe anaemia and
a low birth weight (LBW) outcome, a leading cause of
child mortality and poor growth and development [3-7].
Malaria in pregnancy and its adverse consequences can be
prevented with suppressive antimalarial treatment or che-
moprophylaxis [8]. Weekly chloroquine (CQ) has been
the basis for prevention for many years, but now has lim-
ited application. There are difficulties in coverage and
compliance throughout pregnancy and parasite resistance
to CQ has effectively made its use redundant in P. falci-
parum endemic areas [9,10]. A new strategy for prevention
based on insecticide-treated bed nets (ITNs) and use of
intermittent preventive treatment in pregnancy (IPTp) has
been formulated [1,11]. IPTp is based on the administra-
tion of treatment doses of sulphadoxine-pyrimethamine
(1500/75 mg; SP) to all pregnant women at pre-defined
intervals and regardless of malaria infection. Currently,
WHO recommends administering SP two or three times at
scheduled antenatal visits at least one month apart from
the second trimester onwards [1]. Evidence of the efficacy
of IPTp with SP for preventing malaria infection and
improving birth weight was reported from East Africa
[3,12,13] and West Africa [14,15].
IPTp assumes that the large majority of pregnant women
attend antenatal clinics (ANC) at least twice during their
pregnancy and at a time when SP can be administered
under direct observation. Unfortunately, late attendance
to ANC and weak health services limit the effectiveness of
this strategy [16-19]; coverage with two or more SP doses
varies widely (24–68%) [20] and is well behind the goal
of 80% proposed by the Roll Back Malaria Partnership
[11,21]. New approaches to increase IPTp coverage are
urgently needed.
In Burkina Faso, CQ and SP have been used as first and
second line treatment for uncomplicated malaria until
2005. Parasitological resistance to CQ was 18% in chil-
dren in Bobo-Dioulasso in 1998–2000 [22] while ade-
quate clinical and parasitological response (ACPR) in
pregnant women in Ouagadougou was 53.3% (Day 28) in
2003 [23]. Resistance to SP was similar in children and
pregnant women in 2003 with ACPR (D28) of 91.8% and
87.1% respectively [23,24].
This study investigated whether promoting regular and
early antenatal attendance of pregnant women through
community based health education would increase cover-
age and uptake of IPTp and consequently improve preg-
nancy outcomes. In addition, the effectiveness of IPTp-SP
compared with weekly CQ was determined in order to
provide additional evidence to the Burkinabe Ministry of
Health for an impending policy change.
Methods
Study site
The study was carried out between 2003 and 2006 in
Western Burkina Faso, in Boromo Health District (BHD),
a rural province with an estimated total population of
204,117 (Figure 1). There are three seasons: a rainy season
(June to October; 20–35°C; mean annual rainfall about
800 mm/year), a cold dry season (November to February,
16–32°C) and a hot dry season (March to May, 25–
40°C). Malaria is holo-endemic, with high transmission
between July and December. At the time of the study,
national guidelines for malaria prevention in pregnant
women recommended a full treatment course of CQ
(1500 mg over 3 days) at the first antenatal visit followed
by 300 mg weekly until 6 weeks post partum. Antenatal
care was offered free of charge and included, besides CQ
prophylaxis, an ANC card, physical examination, counsel-
ling, and haematinic supplementation (200 mg ferrous
sulphate and 0.25 mg folic acid). In rural Burkina Faso,
antenatal coverage for at least one visit was about 70%,
with 22.5% of first visits during the first trimester and
68.5% of deliveries occurring at home [25].
Study design and randomization
Study interventions were implemented at two different
levels: IPTp with SP (two observed doses at the beginning
of the second and third trimester) was introduced through
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antenatal clinics in selected health centres (HC) and pro-
motional activities were conducted at village level.
Four out of 26 peripheral HC in BHD were strategically
assigned to community promotion in addition to IPTp-SP
(Intervention A). Geographically contiguous HC were
selected to avoid contamination due to the spread of the
promotional campaign across the study arms (Figure 1).
Communities were informed about the dangers of
malaria for the pregnant women and their babies and
early and regular ANC attendance was promoted to ensure
timely IPTp-SP uptake. In 18 villages, female community
leaders were trained to promote specifically designed
health messages using image boxes for individual and
group discussions. These messages were based on a previ-
ous socio-anthropological survey investigating local per-
ceptions and beliefs.
Eight HC were randomly allocated to either implement
IPTp-SP in antenatal clinics without these enhanced pro-
motional activities (Intervention B) or continue with
weekly CQ according to the national guidelines (Con-
trol).
The total study area covered a population of about 75,000
people distributed in 57 villages. Catchment areas of the
selected HC varied in number of villages (2–10) and pop-
ulation size (3,500–10,500). In one catchment area
(Oury), a new HC (Mou) was opened during the study
period, reducing the distance to the nearest HC for two
villages. SP was available at ANC from April 2004. The
promotional activities in the intervention villages started
in May 2004 and continued until June 2006. In August
2004, as part of an additional nutritional study, HC were
in a factorial design assigned to one of two forms of
Location of study health centres and dependant villages in Boromo Health District, Burkina FasoFigure 1
Location of study health centres and dependant villages in Boromo Health District, Burkina Faso.
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micronutrient supplementation: (a) standard haematinics
or (b) daily multi-micronutrients [26].
Enrolment and follow-up
Trained women field assistants (WFA) identified pregnant
women by monthly village visits using a screening ques-
tionnaire. After obtaining an informed consent, women
in their first or second pregnancy were recruited. A ques-
tionnaire on demographic and household characteristics,
education and socio-economic status, obstetrical history,
antenatal visits, illness and treatment during the current
pregnancy was administered by the WFA. Uterine fundal
height was measured to confirm pregnancy and to esti-
mate the gestational age. If the uterus was non-palpable, a
urine pregnancy test was performed. Enrolled women
received a card with a unique study number to be shown
any time they attended a HC. At around 32 weeks of ges-
tation, WFA visited the enrolled women and administered
a questionnaire on antenatal visits, morbidity and treat-
ment received. A capillary blood sample (finger prick) for
packed cell volume (PCV) and parasitaemia was collected.
ANC visits
At each ANC visit, information on previous illnesses and
treatments was collected; fundal height and axillary tem-
perature were measured. Numbers of tablets of directly
observed SP treatment and other medicines (CQ, haema-
tinics) handed to mothers were recorded on a study ques-
tionnaire. Similar information was collected at
unscheduled visits.
Delivery
About half of deliveries were expected to take place at
home assisted either by a traditional birth attendant
(TBA) or a family member. Around the expected time of
delivery, WFA weekly visited women likely to deliver at
home. As soon as possible after delivery, babies were
weighed using a hanging weighing scale (UNICEF Scale,
infant, spring, 5 kg × 25 g) and length was measured to the
nearest half centimetre using a transportable measuring
board (SECA 210 Measure Mat II). A capillary blood sam-
ple for PCV and parasitaemia was collected from the
mother. Whenever possible, WFA cut a small piece of tis-
sue from the middle third of the maternal side of the pla-
centa and prepared a smear after swabbing it on blotting
paper. Similar samples and information were collected
from women delivering at a HC or district hospital in the
study area.
Child survival
Women recruited in the study and their offspring were vis-
ited by WFA about one year after delivery; if the child had
died, the time of the event and its circumstances were
recorded.
Laboratory investigations
All laboratory tests were performed by three experienced
technicians in the laboratory of Boromo District Hospital.
Malaria parasitaemia
Thick films and methanol fixed placental smears were
stained with 10% Giemsa for 10 minutes. For peripheral
blood, parasite density was determined by counting para-
site asexual forms per 200 white blood cells (WBC). The
parasite density per μl was estimated assuming 8,000
WBC/μl. A slide was considered negative if no parasite was
found after counting 500 WBC. All slides were systemati-
cally read by two technicians and for discrepant results a
third consensus reading was performed. Parasite density
for placental smears was expressed as the percentage of
parasitized red blood cells (RBC) over the total number of
RBC after counting at least 1,000 RBC.
Haematology
Heparinized capillary tubes containing whole blood were
centrifuged within 48 hours after collection and PCV read.
To minimize losses during the transport two capillaries
were collected from the same finger prick. If two results
were available the mean value was computed.
Definitions
Malaria infection
Asexual P. falciparum parasites of any density, in a thick
film of peripheral blood (peripheral parasitaemia) or a
placental smear (placental parasitaemia).
Anaemia
PCV < 33%; women were further divided according to the
degree of anaemia, i.e. moderate to severe anaemia PCV <
30%; severe anaemia PCV < 24%. For the analysis of the
haematological status at delivery, only blood samples col-
lected at the day of delivery were considered.
Birth weight
Weight values obtained within 24 hours of delivery were
analysed as such. Weights obtained between day 1–8 post-
delivery were corrected for the physiological fall (D1 4%,
D2 3%, D3 3%, D4 1%) and increase (D5 0%, D6 1%, D7
2%, D8 4%) in weight occurring during the first week after
delivery. The correction factor was estimated by weighing
132 newborns with known birth weight every two days up
to 8 days after delivery. The birth weight analysis includes
only singleton live births. Low birth weight (LBW) is
defined as a corrected birth weight < 2,500 grams.
Gestational age
Fundal height measurements, when compared with deliv-
ery dates, were shown to be inaccurate for estimating the
gestational age. Thus, gestational age at first antenatal visit
was estimated using the time between first ANC visit and
Malaria Journal 2008, 7:180 http://www.malariajournal.com/content/7/1/180
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delivery [27], assuming delivery occurred after 40 weeks
gestation. Women were considered in the first trimester
when their first antenatal visit was 25 to 40 weeks before
delivery, in the second if between 13 to 24 weeks and in
the third if between 0 and 12 weeks. Analyses including
gestational age were restricted to normal deliveries of sin-
gleton live-births. Due to the uncertainty of gestational
age, no attempt to define preterm delivery and to distin-
guish between miscarriages and stillbirths was done.
Season
Low transmission from January through June and high
transmission from July through December, based on
locally obtained rainfall and malaria prevalence, and tak-
ing into account the delay between onset of rains and
onset of malaria transmission. All deliveries and blood
samples were thus assigned to a period of either "low" or
"high" transmission. In addition, for birth weight analysis
the low transmission period was sub-divided into "early"
(January to March) and "late" (April to June) low trans-
mission.
Wealth-index
A relative index of socio-economic status based on the
construction material of the house and roof and house-
hold assets (bicycle, motorbike, cart, car, television, radio,
cell phone) was constructed using principal component
analysis [28,29]. Classes were derived by dividing the
index into quartiles graded as most poor, poor, less poor
and least poor.
Distance
Mean distances between villages and the nearest HC are
those used by BHD for the vaccination program and are
consistent with our own GPS derived data.
Data analysis
Sample size
Assuming a mean birth weight of 2,600 grams with no
intervention and accounting for the cluster (village) effect
with a small coefficient of variation between clusters in
each group, the study was designed to detect, at the 5%
level and with 80% power, a difference in mean birth
weight of 200 grams between study arms. With 50
expected pregnancies per 1,000 inhabitants per year, one
third first or second pregnancies, and allowing for 20%
loss to follow-up, a total population of 70,000 was
needed for including and following up 2,000 primi- and
secundigravidae in two years.
Statistical analysis
Access 2003 was used for double data entry and validation
and EpiInfo 2000 (version 3.2.2; Centers for Disease Con-
trol and Prevention, Atlanta) and STATA (Intercooled ver-
sion 10; Stata Corp., College Station, TX) software
packages were used for analysis. Initially villages were
intended to be considered as the sampling unit. However,
as HC were the units of randomization, it was decided to
account for the cluster design using linearized variance
estimations with HC as the primary sampling unit (svyset
HC, vce (linearized) in STATA 10). Baseline characteristics
were compared between study arms using a design-based
Pearson χ2-test (svy linearized: tabulate in STATA 10). Lin-
ear regression models (svy linearized: regress) were used
to compare means of birth weight and PCV and logistic
regression models (svy linearized: logistic) to compare
proportions of ANC and IPTp-SP coverage, parasitaemia,
anaemia and LBW and to determine odds ratios with cor-
responding 95% confidence intervals (CI). The criterion
for statistical significance was set at alpha = 0.05. Variables
tested as possible confounders were age (dichotomized ≤
19/> 19 years), parity, education, marital status, wealth
index, bed net ownership, season, distance (dichot-
omized ≤ 5/> 5 km) and, for birth weight analyses, sex of
the baby. Variables associated with outcomes at a signifi-
cance level with p < 0.1 in univariate analysis were entered
in multiple logistic regression models. Intervention arm
was kept as a variable in all models.
Final sample
Women enrolled during the first months of the study were
likely to have started antenatal clinics before the interven-
tions were implemented and have already received CQ
chemoprophylaxis instead of IPTp-SP. The intervention A
arm would not have been exposed to promotional activi-
ties. Therefore, women in their 4th or later month of preg-
nancy at the time the study started (delivery date prior to
September 1st 2004) were excluded a priori from the anal-
ysis.
Ethical clearance
The study was approved by the Burkina Faso Ministry of
Health and the Ethical Committee at ITM, Antwerp. Local
health authorities and community leaders were informed
about the study objectives and procedures for data collec-
tion. All study participants gave informed consent after
explanation of the procedures in the local language and
were free to remove consent at any time of the study with-
out influencing their access to health services. Women
found to be parasitaemic or anaemic at 32 weeks or at
delivery were offered antimalarial treatment (either qui-
nine in the intervention arms or CQ in the control arm)
and extra haematinics according to national guidelines.
Results
Enrolment and follow up
Between April 2004 and March 2006, WFA identified
6,339 pregnant women, 2,884 in their first or second
pregnancy, 2,766 of whom were enrolled (Figure 2). Dur-
ing the study period, eight women withdrew consent and
Malaria Journal 2008, 7:180 http://www.malariajournal.com/content/7/1/180
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208 (8.2%) were lost to follow-up, resulting in 2,550
pregnancies with known outcome. Two hundred and sixty
two women delivered before September 1st, 2004 and
were excluded from the analysis. Six women died, three
during pregnancy (one bacterial meningitis despite hospi-
tal treatment, one unsafe abortion at home and one
unknown disease at home), one at delivery and two after
delivery (unknown cause). WFA did 1,780 home visits for
blood sampling at around 32 weeks of gestation, covering
77.8% of women with known pregnancy outcomes.
Missed visits were mainly due to the high mobility of the
study subjects. About two thirds of deliveries took place in
a HC (62.7%; 1,434/2,288). At 32 weeks gestation hae-
matological and parasitological data were available for
about 70–80% of women, with a similar proportion at
delivery for HC deliveries and about 20% for home deliv-
eries. Birth weight within one week after delivery was col-
lected for almost 90% of singleton live-births (Table 1).
Women's characteristics
Study participants were mainly young women (mean age
19.7 years) without formal education, mostly married and
living within 5 km from the nearest HC. Women in the
intervention A arm were slightly older than in the inter-
vention B and control arms and less likely to have a fund
raising activity. The wealth index was skewed towards the
poorer category in the control arm and towards the less
poor in the intervention A arm. Nevertheless, most varia-
bles at baseline were comparable between study arms
(Table 2).
Study design, enrolment and follow-up of study participants, Boromo Health District, Burkina Faso (2004–2006)Figure 2
Study design, enrolment and follow-up of study participants, Boromo Health District, Burkina Faso (2004–
2006). * 18 near term in March-April 2004. † 3 not pregnant, 1 delivered before enrollment, 55 near term in March-April 
2004. ‡ 2 not pregnant, 29 near term in March-April 2004. §delivered before 1st Sept 2004.
Boromo Health District (pop. 204,117)
26 peripheral Health Centres (HC)
4 HC (pop. 24,534)
Intervention A
IPTp-SP + Promotion
4 HC (pop. 25,953)
Intervention B
IPTp-SP – no promotion
4 HC (pop. 25,323)
Control
Weekly CQ – no promotion
Arbitrarily assigned
Randomly selected
Pregnant women screened
(n=1912)
Pregnant women screened
(n=2353)
Pregnant women screened
(n=2074)
Lost to follow-up (n=91)
Moved (n=91)
Not in analysis§ (n=88)
Lost to follow-up (n=67)
Moved (n=60)
Withdraw consent (n=7)
Not in analysis§ (n=93)
Lost to follow-up (n=58)
Moved (n=57)
Withdraw consent (n=1)
Not in analysis§ (n=81)
Excluded (n=990)
Gravida 3 (n=971)
No consent (n=1)
Other* (n=18)
Excluded (n=1392)
Gravida 3 (n=1324)
No consent (n=9)
Other† (n=59)
Excluded (n=1191)
Gravida 3 (n=1160)
Other‡ (n=31)
Analysed (n=743)
Singleton live-births (n=686)
Twins (n=15)
Miscarriage/Stillbirths (n=41)
Maternal deaths (n=1)
Analysed (n=801)
Singleton live-births (n=755)
Twins (n=13)
Miscarriage/Stillbirths (n=33)
Maternal deaths (n=0)
Analysed (n=744)
Singleton live-births (n=699)
Twins (n=7)
Miscarriage/Stillbirths (n=36)
Maternal deaths (n=2)
Gravidae 1 and 2 enrolled
(n=922)
Gravidae 1 and 2 enrolled
(n=961)
Gravidae 1 and 2 enrolled
(n=883)
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Effect of the promotional campaign on IPTp-SP uptake
ANC attendance
The great majority (95.6%; 2,187/2,288) of study partici-
pants attended ANC at least once during pregnancy, but
only half (50.0%; 1,143/2,288) attended three or more
times (Table 3). The proportion of women with three or
more ANC visits was higher with (intervention A) than
without promotion (intervention B and control com-
bined) (OR 2.1 95%CI 0.95–4.65 p = 0.063). About one
quarter of the women (26.6%; 569/2,137) had their first
ANC visit during the third trimester. This was significantly
less frequent in the promotion (18.7%) than in the two
non-promotion arms (29.6%) (OR 0.55 95%CI 0.36–
0.84 p = 0.011). The proportion of women having
received at least 2 doses of SP was significantly higher in
the intervention A than in the intervention B arm (69.9%
vs. 48.6%; OR 2.45, 95% CI 1.25–4.82 p = 0.014).
Effectiveness of IPT-SP with and without promotional 
campaign
Parasitological outcomes
Peripheral parasitaemia during pregnancy and at delivery
At 32 weeks of gestation, the prevalence of malaria infec-
tions, all P. falciparum, was 23.0% (408/1,773) and varied
significantly with season, i.e. 35.0% (302/863) during the
high transmission period and 11.6% (105/904) during
the low transmission period (OR 4.1 95% CI 2.91–5.77 p
< 0.001). Primigravidae were more frequently infected
than secundigravidae (26.2% vs. 19.5%; OR 1.47 95% CI
1.02–2.11 p = 0.040). Peripheral parasitaemia prevalence
at delivery showed a similar pattern with an overall para-
site rate of 23.2% (326/1,403), reaching 37.7% (259/
688) in the high transmission period compared to 9.0%
(64/709) during the low transmission period (OR 6.08
95%CI 3.37–10.98 p < 0.001). Primigravidae were more
likely to be infected at delivery than were secundigravidae
(28.2% vs. 17.1%; OR 1.90 95%CI 1.41–2.55 p = 0.001).
Malarial infection, both at 32 weeks and at delivery, was
significantly more frequent in the control arm (32 weeks
29.9%; delivery 33.3%) than in either of the intervention
arms (intervention A: 20.3% and 17.4%; intervention B:
19.4% and 20.1%), although there was no difference
between the two IPTp arms. After adjustment for parity
and season, the probability of peripheral parasitaemia at
delivery was significantly reduced by 68% with interven-
tion A (AOR 0.32 95% CI 0.23–0.44 p < 0.001) and by
61% with intervention B (AOR 0.39 95% CI 0.27–0.57 p
< 0.001) as compared to the control arm.
Placental parasitaemia
The prevalence of placental malaria was 22.7% (310/
1,363), most infections occurring during the high trans-
mission season (38.8% vs.7.1% in low transmission; OR
8.2 95% CI 4.6–14.7 p < 0.001), and in primigravidae
(27.6% vs. 16.7% in secundigravidae; OR 1.9 95% CI 1.4–
2.5 p < 0.001). The prevalence was lower in the interven-
tion groups (intervention A: 18.1%; intervention B:
20.5%) than in the control group (30.3%). Parity and sea-
son adjusted odds ratios (AOR) were 0.38 (95% CI 0.28–
0.51 p < 0.001) for intervention A and 0.47 (95% CI
0.32–0.70 p = 0.002) for intervention B compared with
the control group. The difference between intervention A
and intervention B was not significant (AOR 0.79 95%CI
0.51–1.23 p = 0.268).
Haematological outcomes
Anaemia during pregnancy and at delivery
Overall mean PCV was 32.2 (95%CI 31.6–32.8) at 32
weeks gestation and 34.4 (95%CI 33.6–35.2) at delivery
Table 1: Available outcome measures for primi- and secundigravidae by place of delivery, Boromo Health District, Burkina Faso 
(2004–2006)
Place of delivery
Outcome, n (%) All women Health Centre Home Other
32 weeks n = 2288 n = 1434 n = 806 n = 48*
PCV 1698 (74.2) 1106 (77.1) 583 (72.3) 9 (18.8)
Thick film 1773 (77.5) 1157 (80.7) 607 (75.3) 9 (18.8)
Delivery n = 2285 n = 1434 n = 806 n = 45
PCV any 1696 (74.2) 1100 (76.7) 585 (72.6) 11 (24.4)
PCV < 24 h 1212 (53.0) 1048 (73.1) 158 (19.6) 6 (13.3)
Thick film any 1916 (83.9) 1286 (89.7) 618 (76.7) 12 (26.7)
Thick film < 24 h 1403 (61.4) 1223 (85.3) 173 (21.5) 7 (15.6)
Placental smear 1363 (59.6) 1222 (85.2) 135 (16.7) 6 (13.3)
Birth weight† n = 2140 n = 1364 n = 764 n = 12
< 24 h 1501 (70.1) 1328 (97.4) 166 (21.7) 7 (58.3)
1–8 days 364 (17.0) 32 (2.3) 330 (43.2) 2 (16.7)
PCV = packed cell volume
* including 3 women who died during pregnancy
† only singleton live births
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and was lower, though not significantly, in the control
arm compared with the two intervention arms combined
(Figure 3).
Risk factors for anaemia (PCV < 33) at 32 weeks in univar-
iate analysis were primiparity (OR 1.33 95%CI 1.06–1.66
p = 0.016) and high transmission season (OR 1.57 95%CI
1.19–2.09 p = 0.005), bed net ownership had a protective
effect (OR 0.81 95%CI 0.7–0.93 p = 0.007). At delivery,
risk factors for anaemia included primiparity (OR 1.41
95%CI 1.07–1.84 p = 0.018), season (OR 1.5 95%CI
1.08–2.07 p = 0.019) and poor wealth index (OR 1.42
95%CI 1.09–1.85 p = 0.014).
The prevalence of anaemia (PCV < 33) was higher in the
control arm (32 weeks: 56.4%; delivery: 40.3%) than in
the intervention arms (intervention A: 49.4% and 30.8%;
intervention B: 48.7% and 32.7%), but none of the differ-
ences in pair-wise and grouped (intervention A and B vs.
control) comparisons reached statistical significance
Table 2: Baseline characteristics of study participants (n = 2,288), Boromo Health District, Burkina Faso (2004–2006)
Study arm
Characteristic All women
n = 2288
Intervention A
n = 743
Intervention B
n = 801
Control
n = 744
Age
Median (range), years 19 (14–41) 20 (14–41) 19 (15–37) 19 (15–35)
≤ 19 years 54.1 45.9 60.8 55.1
Gravidity
Primigravidae 55.6 57.1 56.2 53.6
Previous pregnancy outcome if secundigravid †:
Miscarriage or stillbirth 13.0 15.7 11.7 11.9
Child death* 16.7 12.9 17.4 19.4
Formal education (any school)
Mother 21.5 25.3 18.1 21.4
Father ‡ 26.6 29.1 28.0 22.6
Activity
Mother with own income 69.3 52.6 79.3 75.3
Father farmer/breeder 92.9 87.9 94.8 93.5
Wealth Index* §
most poor 22.7 14.2 22.7 31.3
poor 27.2 24.3 24.7 33.0
less poor 24.9 19.6 32.7 22.1
least poor 25.1 42.0 19.9 13.6
Marital status of mother
Not married 5.1 6.1 4.4 4.8
Religion
Muslim 48.0 57.5 44.9 41.8
Christian 19.1 22.3 16.5 18.8
Traditional 32.9 20.2 38.6 39.4
Ethnic group*
Bwaba/Dafing 53.9 12.9 69.2 78.5
Ko/Nounouma 24.1 60.8 10.7 1.9
Mossi 11.3 16.3 11.1 6.6
Fulani 5.5 5.2 7.1 4.0
Other 5.1 4.7 1.9 9.0
Distance from nearest HC (km)
≤ 5 73.0 76.9 61.3 81.7
> 5 27.0 23.2 28.7 18.3
Bed net*
Owns bed net at enrolment 30.2 35.1 35.8 19.1
Intervention A = IPTp+promotion; Intervention B = IPTp alone; Control = CQ chemoprophylaxis; HC = health centre
Numbers are proportions if not otherwise stated.
* Proportions significantly different between study arms
† Intervention A n = 319; Intervention B n = 351; Control n = 345
‡ Intervention A n = 690; Intervention B n = 768; Control n = 721
§Intervention A n = 741; Intervention B n = 787; Control n = 737
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(Table 3). Differences between study arms remained non
significant after adjustment for parity, season, bed net
ownership and wealth index.
The prevalence of severe anaemia (PCV < 24) was below
5%, both at 32 weeks (2.9%, 95%CI 1.9–3.9) and at deliv-
ery (3.2%, 95%CI 1.9–4.9) and did not significantly differ
between study arms.
Birth outcomes
Overall mean birth weight of live singletons was 2,822 g
(95%CI 2,782–2,862); 2,720 g (95%CI 2,674–2,766) for
primigravidae and 2,945 g (95%CI 2,893–2,997) for
secundigravidae (p < 0.001). LBW was associated with
placental malaria only in primigravidae (OR 2.4 95%CI
1.5–3.9 p = 0.002) but not in secundigravidae (OR 0.84
95%CI 0.37–1.93 p = 0.661). Mean birth weight did not
significantly differ between study arms (Figure 4) though
the prevalence of LBW compared to weekly CQ was
reduced by 27% (from 22.3 to 18.6) with intervention A
and by 17% (from 22.3 to 16.2) with intervention B
(Table 3). However, even after adjusting for parity, season,
sex of the baby, distance, and bed net ownership none of
these differences was significant (intervention A vs. con-
trol: AOR 0.64 95%CI 0.38–1.10 p = 0.097; intervention
B vs. control: AOR 0.71 95%CI 0.37–1.35 p = 0.271).
The proportion of miscarriage or stillbirth among women
with known pregnancy outcome was not significantly dif-
ferent between study arms.
Discussion
In this community-based trial, the effect of providing
IPTp-SP through routine ANC coupled with promotional
activities targeted to pregnant women was assessed by
comparing parasitological, haematological, and birth
weight outcomes in primi- and secundigravidae. At the
time this study was implemented, the national prevention
policy for pregnant women was weekly CQ chemoproph-
ylaxis and the Burkinabe Ministry of Health had requested
more local data on IPTp-SP prior to changing the policy.
Therefore, the effectiveness of IPTp-SP was measured by
comparing two intervention arms where HC provided
IPTp-SP with a control arm where HC offered weekly CQ
Table 3: Comparison of main outcome measures by study arm, Boromo Health District, Burkina Faso (2004–2006)
Study arms Comparisons
Intervention
Characteristic A B Control A vs. Control B vs. Control A vs. B
% (n/N) OR (95%CI)
Antenatal care
≥ 3 ANC visits 62.3 (463/743) 42.3 (339/801) 45.8 (341/744) 1.95 (0.86–4.45) 0.87 (0.36–2.10) 2.25 (0.86–5.92)
1st ANC visit in third 
trimester †
18.7 (127/679) 28.5 (199/699) 30.8 (205/666) 0.52 (0.26–1.03) 0.90 (0.47–1.70) 0.58** (0.44–0.76)
≥ 2 doses IPT-SP 69.9 (519/743) 48.6 (389/801) 2.45* (1.25–4.82)
Home visit at 32 weeks
Anaemia (PCV < 33) 49.4 (288/583) 48.7 (285/585) 56.4 (299/530) 0.75 (0.37–1.54) 0.73 (0.36–1.50) 1.03 (0.68–1.56)
Moderate/severe anaemia 
(PCV < 30)
23.8 (139/583) 27.7 (162/585) 30.2 (160/530) 0.72 (0.39–1.34) 0.89 (0.45–1.73) 0.82 (0.62–1.08)
Peripheral parasitaemia 20.3 (121/597) 19.4 (120/618) 29.9 (167/558) 0.60* (0.39–0.91) 0.56** (0.40–0.80) 1.05 (0.67–1.67)
Delivery
Anaemia (PCV < 33) ‡ 31.1 (137/440) 32.8 (131/399) 40.2 (150/373) 0.67 (0.38–1.18) 0.73 (0.39–1.36) 0.92 (0.51–1.69)
Moderate/severe anaemia 
(PCV < 30) ‡
16.8 (74/440) 16.8 (67/399) 19.8 (74/373) 0.82 (0.46–1.46) 0.82 (0.46–1.46) 1.00 (0.58–1.72)
Peripheral parasitaemia‡ 17.4 (87/499) 20.1 (95/472) 33.3 (144/432) 0.42*** (0.30–0.60) 0.50** (0.37–0.69) 0.84 (0.60–1.18)
Placental parasitaemia 18.1 (89/491) 20.5 (90/440) 30.3 (131/432) 0.51** (0.37–0.70) 0.59* (0.44–0.78) 0.86 (0.58–1.29)
Low birth weight (< 2500 
grams) §
16.2 (95/585) 18.6 (128/687) 22.3 (132/593) 0.68 (0.42–1.08) 0.80 (0.46–1.39) 0.85 (0.61–1.17)
Miscarriage/stillbirths || 5.5 (41/742) 4.1 (33/801) 4.9 (36/742) 1.15 (0.89–1.48) 0.84 (0.55–1.28) 1.36 (0.88–2.12)
Intervention A = IPTp+promotion; Intervention B = IPTp alone; Control = CQ chemoprophylaxis; ANC = antenatal care; PCV = packed cell 
volume; OR = odds ratio; CI = confidence interval.
The non-adjusted risk estimates are presented as these did not change when adjusted for possible confounders.
* p < 0.05; ** p < 0.01; *** p < 0.001;
† singleton live-births only;
‡ only samples taken the day of delivery;
§ live born singletons weighed within 8 days after delivery;
|| 3 maternal deaths not included
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while the added value of the promotional campaign tar-
geted to pregnant women was assessed between interven-
tion arms with and without promotion. Despite good
coverage with more than two thirds of primi- and secundi-
gravidae in the intervention villages with promotion hav-
ing taken at least two SP doses, no significant
improvement in the haematological and birth weight out-
comes was observed. It should be noted that when the
effect of the IPTp-SP is analysed at individual level (and
not by community), women having received two or more
SP doses had a significantly lower risk of peripheral and
placental parasitaemia (10.8% and 12.2% respectively),
anaemia (13.7% PCV < 30%) and low birth weight
(12.8%). This indicates that a major impact of IPTp-SP at
community level can be detected only when, as with
immunization programmes, the coverage is extremely
high. In this setting, reaching the current RBM goal of 80%
by 2010 [11] is unlikely to result in a major impact. The
critical threshold of coverage yet needs to be defined, pos-
sibly on a regional basis. These results also illustrate the
difficulty of translating an efficacious intervention into an
effective policy.
IPTp-SP performed better than weekly CQ in clearing
peripheral and placental parasitaemia, even at a relatively
low coverage (2 or more SP doses < 50% without promo-
tion). This finding strongly supports the policy change to
IPTp-SP in Burkina Faso, decided in early 2005 [30]. The
Mean PCV during pregnancy and at delivery by study arm, Boromo Health District, Burkina Faso (2004–2006)Figure 3
Mean PCV during pregnancy and at delivery by study arm, Boromo Health District, Burkina Faso (2004–2006). 
Intervention A = blue l; Intervention B = green n; Control = red Δ. Numbers next to symbols represent point estimates of 
the mean; error bars represent 95% confidence intervals.
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remaining relatively high rates of placental malaria occur-
ring mainly during the high transmission season in the
IPTp-SP groups are consistent with other studies in the
region and are likely to be due to high rates of reinfection
after the last dose of SP [14,15,31] rather than to SP-resist-
ance. Resistance to SP in urban and rural settings was not
widespread at the time the study was conducted [23,24]
and it is unlikely that local differences in SP resistance in
the study area have significantly influenced the results.
Maternal anaemia and LBW, two major consequences of
malaria infection during pregnancy, were only marginally
affected by the intervention. Evidence that IPTp-SP
reduces anaemia and increases birth weight in primi- and
secundigravidae is mainly based on trials where the con-
trol group received no treatment [8]. Only three studies
directly compared IPTp-SP with weekly CQ, all in women
of low parity. In Malawi, a 70% decrease in placental
malaria with a mean gain in birth weight of 116 grams
was observed, with no data on anaemia reported [13]. In
Mali, a moderate reduction of placental malaria with a
mean birth weight gain of 33 grams and 30% reduction in
anaemia was reported, but with no effect on severe anae-
mia [14]. Recently, in Burkina Faso, in an urban setting
where placental malaria prevalence was below 6%, no dif-
ference in mean haemoglobin and birth weight between
IPTp-SP and weekly CQ was found [32]. Overall, the
greatest impact of IPTp-SP on malaria prevalence has been
Mean birth weight of live-born singletons by study arm, Boromo Health District, Burkina Faso (2004–2006)Figure 4
Mean birth weight of live-born singletons by study arm, Boromo Health District, Burkina Faso (2004–2006). 
Intervention A = blue l; Intervention B = green n; Control = red Δ. Numbers next to symbols represent point estimates of 
the mean; error bars represent 95% confidence intervals.
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observed in East Africa, where CQ resistance was high. The
smaller difference between IPTp-SP and weekly CQ
observed in West Africa, for example in Mali or Burkina
Faso, suggests that weekly CQ chemoprophylaxis may still
have some preventive effect, reducing then the difference
between intervention and control groups. Indeed, in the
Burkina Faso capital, Ouagadougou, adequate clinical
and parasitological response at day 28 post-treatment in
pregnant women treated with CQ was above 50% [23];
the success rate in rural communities, such as those
involved in the current study, is probably higher [33].
Therefore, the remaining effectiveness of CQ chemo-
prophylaxis in the control group may explain the little
effect on anaemia and birth weight observed in both inter-
vention groups. This is consistent with the strong associa-
tion between non-attendance at ANC and peripheral
parasitaemia at any time during pregnancy observed in
cross-sectional surveys undertaken before the introduc-
tion of IPTp in the same study area and with recent data
from neighbouring Benin [34,35].
Antenatal care providers in HC where IPTp-SP was imple-
mented were advised to give two doses of SP to pregnant
women at the beginning of the second and third trimester
as recommended by the WHO guidelines [36]. Since the
start of the study, recommendations have been modified
and simplified; "beginning of the second trimester" has
been replaced by "after quickening", and "third trimester"
by "at least one month apart". This change leaves uncov-
ered the period between the beginning of the second tri-
mester and the onset of quickening. Most countries
implementing IPTp have chosen the two-dose-policy
because the evidence for a beneficial effect of a third dose
was limited to HIV-positive women [37]. In the current
WHO recommended schedule of four ANC, with three
visits after quickening, the frequency of IPTp dosing is no
longer limited to two doses (and three where HIV-preva-
lence is >10%), but IPTp should be given "with each
scheduled visit after quickening" to "assure that a high
proportion of women receive at least two doses" [1].
These simplified recommendations take into account the
difficulty to assess gestational age in busy peripheral ANC
and to decide whether to administer SP. In the present
study, giving SP at every ANC visit after the first trimester
would have resulted in a better coverage with 90% women
with more than two doses (instead of 70%), and 61%
with more than three doses (instead of 4%) in the inter-
vention A arm.
This is the first community-based effectiveness trial on
IPTp-SP examining ways of increasing SP uptake through
existing health services. It offers an interesting insight on
the difficulties of increasing IPTp coverage. Alternative
delivery systems of IPTp within the community have
recently been tested in Uganda and Malawi. In both stud-
ies women receiving SP from community sources less fre-
quently completed ANC, a side effect that may have a
negative impact on women's health (K. Msyamboza, per-
sonal communication) [38]. In the present study, partici-
pants were enrolled at community level but the
randomization unit was the health centre as the main
intervention (IPTp-SP) was related to the ANC. Therefore,
variations between health centres in number of commu-
nities and population covered, as well as mobility and
experience of the health staff, may have contributed to a
larger cluster design effect than initially expected, a limita-
tion of the study. For the intervention, the selection of
health centres was not done randomly but on geographi-
cal contiguousness to avoid contamination (promotion
campaign) between study arms. While known differences
in baseline characteristics (age, ethnic group, wealth
index) could be adjusted for, unknown factors may have
influenced the findings although it is unlikely this would
have resulted in an important bias. Moreover, the difficul-
ties of following up pregnant women in a highly mobile
rural population, often with sub-optimal working condi-
tions in health centres and with a substantial number of
home deliveries, should be appreciated. Despite substan-
tial logistic constraints, our data include both health cen-
tre and home deliveries, and are more likely to reflect "real
life conditions" than most health centre based studies.
It is noteworthy that this study found similar prevalences
for peripheral and placental parasitaemia while the actual
prevalence of parasitaemia is generally underestimated by
peripheral microscopy [39]. The staff in peripheral health
centres was trained to remove excess blood when prepar-
ing placental smears and excessively dried samples may
have limited the number of red blood cells on the slide
thus reducing the sensitivity of placental microscopy.
Moreover, it was not possible to blind microscopists to
the peripheral blood results, a further limitation.
Conclusion
The promotional campaign resulted in a major increase in
coverage, with two thirds of women receiving at least two
SP treatments during pregnancy. Despite their lower prev-
alence of malaria infection this did not translate into a dif-
ference in maternal anaemia or birth weight outcomes
because the remaining proportion (30%) of primi- and
secundigravidae not having received two SP treatments
dilute the impact of the intervention. SP administration at
all ANC visits following the first trimester should dramat-
ically increase coverage. Since differences between groups
with 49% and 70% SP coverage were only marginal, it is
unclear what impact could be observed if the current RBM
goal of 80% by the year 2010 is reached. This data pro-
vides evidence that, as with immunization programmes,
extremely high coverage is essential for effectiveness. This
critical threshold of coverage needs to be defined, possibly
Malaria Journal 2008, 7:180 http://www.malariajournal.com/content/7/1/180
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on a regional basis. On-going active surveillance of SP
uptake should be an important component of all malaria
in pregnancy control activities.
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